Juvenile Arthritis: TNF Inhibitor Use Doesn’t Appear To Increase Malignancy Risk

MedicalResearch.com Interview with:

Timothy Beukelman, MD, MSCE Associate Professor of Pediatrics Division of Rheumatology and Division of Clinical Immunology & Rheumatology University of Alabama at Birmingham

Dr. Timothy Beukelman

Timothy Beukelman, MD, MSCE
Associate Professor of Pediatrics
Division of Rheumatology and
Division of Clinical Immunology & Rheumatology
University of Alabama at Birmingham

MedicalResearch.com: What is the background for this study?

Response: In 2009 the US FDA issued a boxed warning about malignancies reported in children treated with TNF inhibitors but their analysis did not account for a possible malignancy risk from other medications of from the Juvenile idiopathic arthritis (JIA) disease process itself.

Continue reading

Idiopathic Juvenile Arthritis: Effects of MMR Booster Vaccination

Marloes Heijstek MD  University Medical Center, Wilhelmina Children's Hospital Department of Pediatric Immunology and Rheumatology Room number KC 03.063.0 P.O. Box 85090 Lundlaan 6 3508 AB UtrechtMedicalResearch.com Interview with:
Marloes Heijstek MD

University Medical Center, Wilhelmina Children’s Hospital
Department of Pediatric Immunology and Rheumatology
Room number KC 03.063.0
P.O. Box 85090 Lundlaan 6
3508 AB Utrecht

MedicalResearch.com: What are the main findings of the study?

Dr. Heijstek: The main findings of our study are that MMR booster vaccination does not affect JIA disease, does not cause flares of arthritis and induces high rates of protective immunity.
Continue reading